<?xml version="1.0" encoding="UTF-8"?>
<ref id="B4">
 <label>4</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rini</surname>
    <given-names>BI</given-names>
   </name>
   <name>
    <surname>Plimack</surname>
    <given-names>ER</given-names>
   </name>
   <name>
    <surname>Stus</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Gafanov</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Hawkins</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Nosov</surname>
    <given-names>D</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Pembrolizumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma</article-title>. 
  <source>N Engl J Med</source> (
  <year>2019</year>) 
  <volume>380</volume>(
  <issue>12</issue>):
  <page-range>1116â€“27</page-range>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1816714</pub-id>
 </mixed-citation>
</ref>
